Bharat Biotech International Limited (BBIL), a pioneering firm in the field of vaccine development and innovation, declared recently that its iNCOVACC® (BBV154) is set to be introduced in the country shortly as a booster dose. It is priced at INR 800+GST for Private Markets and INR 325+GST for Governments.
This vaccine is planned to be rolled out in the fourth week of January. It is intended for individuals aged 18 and above. iNCOVACC® is the first Intranasal vaccine for COVID to gain approval for a two-dose primary schedule and as an alternate booster dose. The vaccine is a recombinant replication-deficient adenovirus vectored vaccine that carries a pre-fusion-stabilized SARS-CoV-2 spike protein. It has undergone phases I, II, and III of clinical testing with positive results.
About Bharat Biotech
A Recent Achievement in India’s ROTAVIRUS VACCINE – ROTAVAC, enhanced Bharat Biotech International Limited, a global leader in the Vaccine field. The company has over 145 global patents and produced 19 vaccines, four therapeutics, and registrations in 1255 countries.
Yes. You must be above 18 years of age.
COVID Suraksha Program funds Vaccine Development. So it is priced at the lowest of 325 INR for State Governments and Govt of India.
For Private Entities, it costs around 800 INR + GST.
iNCOVACC® recipients showed significant Mucosal IgA antibody levels (calculated in the saliva). Mucosal IgA antibodies in the upper respiratory tract may provide help in decreasing infections and transmission.
Phase I, II, and III trials were successfully evaluated. As a result, the most reliable outcomes for using the vaccine are safety and efficiency against reducing the disease and transmission of SARS-CoV-2.
